TNYA

NASDAQ

Tenaya Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2021

$0.69-0.04 (-5.95%)

News25/Ratings7

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.

Price$0.69-0.03 (-4.59%)

01:30 PM07:45 PM

News · 26 weeks50-71%

2025-10-262026-04-19

Mix3190d

SEC Filings16(52%)
Insider9(29%)
Other5(16%)
Offering1(3%)

Latest news

25 items

7dSEC
SEC Form DEFA14A filed by Tenaya Therapeutics Inc.
DEFA14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)
7dSEC
SEC Form DEF 14A filed by Tenaya Therapeutics Inc.
DEF 14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)
43dSEC
SEC Form 10-K filed by Tenaya Therapeutics Inc.
10-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
43dSEC
Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
43dPR
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301's Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discove
45dPR
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301's Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
49dSEC
Tenaya Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
49dPR
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Agreement Combines Tenaya's Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (NASDAQ:ALNY), the leading RNAi therape
52dPR
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya's Chief Executive Officer, will participate in a fireside chat on Monday, March 9, 2026, at 1:00 pm ET. The live webcast of the fireside chat may be accessed from the Investors section of Tenaya's website. An archived replay
56dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Tenaya Therapeutics Inc.
SCHEDULE 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
56dINSIDER
Large owner Column Group Iii Gp, Lp sold $2,380,189 worth of shares (4,170,266 units at $0.57) (SEC Form 4)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
57dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
57dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
58dINSIDER
Large owner Column Group Iii Gp, Lp sold $504,787 worth of shares (829,734 units at $0.61) (SEC Form 4)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
62dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
62dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
65dINSIDER
SVP, Finance Higa Tomohiro sold $2,231 worth of shares (3,469 units at $0.64), decreasing direct ownership by 3% to 119,752 units (SEC Form 4)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
65dINSIDER
Chief Executive Officer Ali Faraz sold $9,557 worth of shares (14,862 units at $0.64), decreasing direct ownership by 3% to 443,404 units (SEC Form 4)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
65dINSIDER
Chief Medical Officer Tingley Whittemore sold $3,319 worth of shares (5,160 units at $0.64), decreasing direct ownership by 2% to 218,618 units (SEC Form 4)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
65dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
70dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Tenaya Therapeutics Inc.
SCHEDULE 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
70dINSIDER
Large owner Column Group Iii Gp, Lp sold $3,042,222 worth of shares (4,400,290 units at $0.69) (SEC Form 4)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
71dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
71dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
72dSEC
SEC Form 144 filed by Tenaya Therapeutics Inc.
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)